Table 4.
Outcomes | ASCVD < 10% (N = 9,079) |
ASCVD ≥ 10% or prior CHD (N = 3,384) |
P-value |
---|---|---|---|
Fall | 1.01 (0.92, 1.11) | 1.05 (0.84, 1.31) | 0.79 |
Syncope | 1.00 (0.90, 1.10) | 1.10 (0.88, 1.38) | 0.40 |
CHD | 0.84 (0.74, 0.95) | 0.99 (0.84, 1.17) | 0.015 |
Death | 0.89 (0.82, 0.96) | 1.03 (0.91, 1.17) | 0.019 |
Values are given as hazards ratio (95% confidence interval). Reduced sample size (N = 12,463) for ASCVD analysis due to missing low-density lipoprotein cholesterol data. Models are adjusted for age, sex, race-center, estimated glomerular filtration rate, body mass index, resting heart rate, high-density lipoprotein cholesterol, total cholesterol, prevalent CHD, prior stroke, prevalent heart failure, diabetes mellitus status, hypertension status, self-reported dizziness, alcohol consumption, education level, leisure index, smoking status, antihypertensive medication use in the last two weeks, and use of diuretics, antidepressants, sedatives, hypnotics, antipsychotics, and cholesterol-lowering medications. Participants were followed up through December 31, 2019, for a median of 24 years of follow-up. Abbreviations: ASCVD, baseline 10-year atherosclerotic cardiovascular disease risk; CHD, coronary heart disease; SBP, systolic blood pressure.